Erasca (ERAS) Change in Acquisitions & Divestments (2020 - 2026)
Erasca (ERAS) posted Change in Acquisitions & Divestments of $58.6 million for Q1 2026, down 12.55% on a QoQ basis from $67.0 million in Q4 2025, and up 30.11% year-over-year from $45.0 million in Q1 2025.
Erasca (ERAS) Change in Acquisitions & Divestments (2020 - 2026) Analysis & Trends
Erasca's Change in Acquisitions & Divestments history runs 7 years deep, the most recent figure standing at $58.6 million for Q1 2026.
- Quarterly Change in Acquisitions & Divestments rose 30.11% year-over-year to $58.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $274.6 million (up 5.47% YoY) and the FY2025 annual result came in at $261.0 million, down 3.08% from the prior year.
- Change in Acquisitions & Divestments was $58.6 million for Q1 2026 at Erasca, down from $67.0 million in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $89.8 million in Q4 2024 and bottomed at $7.9 million in Q2 2022.
- A 5-year average of $53.7 million and a median of $58.6 million in 2026 frame the typical range for Change in Acquisitions & Divestments.
- Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments sank 47.19% — and 2023, when it jumped 744.94%.
- Erasca's Change in Acquisitions & Divestments stood at $33.9 million in 2022, then surged by 93.94% to $65.7 million in 2023, then soared by 36.51% to $89.8 million in 2024, then dropped by 25.4% to $67.0 million in 2025, then retreated by 12.55% to $58.6 million in 2026.
- Business Quant data shows ERAS's Change in Acquisitions & Divestments at $58.6 million in Q1 2026, $67.0 million in Q4 2025, and $71.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 470.97 Bn | 466.18 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.05 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.42 Bn | 959.66 Mn |
| 10 | Erasca | 5.82 Bn | 5.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.55 Mn |
| Mar 31, 2026 | 58.55 Mn |
| Dec 31, 2025 | 66.95 Mn |
| Dec 31, 2025 | 66.95 Mn |
| Sep 30, 2025 | 71.25 Mn |
| Sep 30, 2025 | 71.25 Mn |
| Jun 30, 2025 | 77.83 Mn |
| Jun 30, 2025 | 77.83 Mn |
| Mar 31, 2025 | 45.00 Mn |
| Mar 31, 2025 | 45.00 Mn |
| Dec 31, 2024 | 89.75 Mn |
| Dec 31, 2024 | 89.75 Mn |
| Sep 30, 2024 | 89.33 Mn |
| Sep 30, 2024 | 89.33 Mn |
| Jun 30, 2024 | 36.25 Mn |
| Jun 30, 2024 | 36.25 Mn |
| Mar 31, 2024 | 54.00 Mn |
| Mar 31, 2024 | 54.00 Mn |
| Dec 31, 2023 | 65.75 Mn |
| Dec 31, 2023 | 65.75 Mn |